• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过序贯使用N-磷乙酰-L-天冬氨酸、大剂量甲氨蝶呤和大剂量5-氟尿嘧啶并进行适当解救,治疗指数得到改善。

Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.

作者信息

Martin D S, Stolfi R L, Sawyer R C, Spiegelman S, Young C W

出版信息

Cancer Res. 1983 Oct;43(10):4653-61.

PMID:6603903
Abstract

Although clinical trials of high-dose methotrexate (MTX) sequenced before 5-fluorouracil (FUra) with leucovorin (LV) rescue apparently have resulted in increased numbers of tumor responses, this increased antitumor activity often has been accompanied with toxicity. The present report describes an attempt to improve therapeutic results with this drug combination by appropriate metabolic modulation in the preclinical BALB/c X DBA/8 F1 murine breast tumor model. A LV rescue schedule consisting of 300 mg/kg administered at 4.5 and 19.5 hr after high-dose MTX (300 mg/kg/week for 3 weeks) prevented MTX toxicity. When FUra was administered 2.5 hr after MTX (with LV rescue), the dose of FUra had to be decreased, and we could not obtain convincing evidence for a differential cytotoxic effect on tumor versus normal host tissue. However, when a delayed uridine rescue schedule was added to protect the host from the toxic activity of FUra, the FUra dose could be increased even in the presence of high-dose MTX, and the therapeutic result was enhanced significantly without an increase in host toxicity. Finally, it was possible to add N-phosphonacetyl-L-aspartate to this drug combination (in the appropriate sequence: N-phosphonacetyl-L-aspartate before high-dose MTX-before high-dose FUra, followed by double rescue with LV and uridine) without producing increased toxicity to yield a significant increase in partial tumor regression rate. The biochemical rationale for the selection and sequence of administration of these agents is discussed.

摘要

尽管在5-氟尿嘧啶(FUra)之前序贯使用高剂量甲氨蝶呤(MTX)并联合亚叶酸(LV)解救的临床试验显然已使肿瘤反应数量增加,但这种增强的抗肿瘤活性常常伴随着毒性。本报告描述了在临床前BALB/c×DBA/8 F1小鼠乳腺肿瘤模型中,通过适当的代谢调节来改善这种药物组合治疗效果的尝试。一种LV解救方案,即在高剂量MTX(300 mg/kg/周,共3周)给药后4.5小时和19.5小时给予300 mg/kg,可预防MTX毒性。当在MTX给药后2.5小时给予FUra(同时进行LV解救)时,FUra的剂量必须降低,而且我们未能获得关于对肿瘤组织与正常宿主组织有不同细胞毒性作用的确凿证据。然而,当添加延迟尿苷解救方案以保护宿主免受FUra的毒性作用时,即使在存在高剂量MTX的情况下,FUra剂量仍可增加,并且治疗效果显著增强,而宿主毒性并未增加。最后,在这种药物组合中加入N-磷酰乙酰-L-天冬氨酸(按照适当顺序:在高剂量MTX之前 - 在高剂量FUra之前,随后用LV和尿苷进行双重解救)不会产生额外毒性,可使部分肿瘤退缩率显著提高。文中讨论了这些药物选择及给药顺序的生化原理。

相似文献

1
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.通过序贯使用N-磷乙酰-L-天冬氨酸、大剂量甲氨蝶呤和大剂量5-氟尿嘧啶并进行适当解救,治疗指数得到改善。
Cancer Res. 1983 Oct;43(10):4653-61.
2
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.晚期癌症患者中应用N-(膦酰乙酰基)-L-天冬氨酸、甲氨蝶呤和5-氟尿嘧啶并联合亚叶酸钙解救的I期试验。
Cancer Res. 1989 Aug 15;49(16):4636-9.
3
Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.低剂量N-(膦酰乙酰基)-L-天冬氨酸与5-氟尿嘧啶联合应用的治疗效用:一项具有临床相关性的小鼠研究
Cancer Res. 1983 May;43(5):2317-21.
4
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.当与N-膦酰基乙酰-L-天冬氨酸、甲氨蝶呤和亚叶酸一起给药时,尿苷可使5-氟尿嘧啶的剂量增加。
Cancer. 1993 Mar 1;71(5):1875-81. doi: 10.1002/1097-0142(19930301)71:5<1875::aid-cncr2820710526>3.0.co;2-9.
5
High-dose 5-fluorouracil with delayed uridine "rescue" in mice.小鼠中高剂量5-氟尿嘧啶联合延迟尿苷“解救”
Cancer Res. 1982 Oct;42(10):3964-70.
6
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Cancer Res. 1994 Mar 15;54(6):1507-10.
7
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.5-氟尿嘧啶与N-(膦酰乙酰基)-L-天冬氨酸生化调节的I期及临床药理学评价
Cancer Res. 1983 May;43(5):2324-9.
8
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Cancer Res. 1994 Aug 15;54(16):4321-6.
9
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.接受 N-(膦酰基乙酰基)-L-天冬氨酸治疗的患者的血清尿苷水平。
Cancer Res. 1980 Aug;40(8 Pt 1):2938-40.
10
Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.高剂量 5-氟尿嘧啶对人乳腺癌的强力联合治疗:缓解和无宿主毒性。
Cancer Chemother Pharmacol. 2012 Jun;69(6):1449-55. doi: 10.1007/s00280-012-1842-x. Epub 2012 Feb 29.

引用本文的文献

1
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).DUP-785(NSC 368390)对嘧啶从头合成的抑制作用。
Invest New Drugs. 1987;5(3):235-44. doi: 10.1007/BF00175293.
2
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.口服尿苷替代胃肠外尿苷用于5-氟尿嘧啶治疗解救的研究,同时使用和不使用尿苷磷酸化酶抑制剂5-苄基阿糖尿苷。
Cancer Chemother Pharmacol. 1989;24(1):9-14. doi: 10.1007/BF00254098.
3
Effect of uridine diphosphoglucose on levels of 5-phosphoribosyl pyrophosphate and uridine triphosphate in murine tissues.
尿苷二磷酸葡萄糖对小鼠组织中5-磷酸核糖焦磷酸和三磷酸尿苷水平的影响。
Pharm Res. 1989 Oct;6(10):863-6. doi: 10.1023/a:1015908505351.